PharmaCyte Biotech (PMCB) Enterprise Value Growth (5y) (2017 - 2026)
PharmaCyte Biotech (PMCB) Enterprise Value Growth (5y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -53.65% |
| Jan 31, 2026 | -46.05% |
| Oct 31, 2025 | -33.23% |
| Jul 31, 2025 | -44.05% |
| Apr 30, 2025 | -76.98% |
| Jan 31, 2025 | -159.55% |
| Oct 31, 2024 | -241.21% |
| Jul 31, 2024 | -150.97% |
| Apr 30, 2024 | -149.86% |
| Jan 31, 2024 | -144.58% |
| Oct 31, 2023 | -140.77% |
| Jul 31, 2023 | -109.93% |
| Apr 30, 2023 | -129.88% |
| Jan 31, 2023 | -117.05% |
| Oct 31, 2022 | -95.69% |
| Jul 31, 2022 | -80.61% |
| Apr 30, 2022 | -89.83% |
| Jan 31, 2022 | -103.80% |
| Oct 31, 2021 | -123.71% |
| Jul 31, 2021 | 16.33% |